Stratified interventions in ARDS (EMINENT)

There is an urgent and unmet need to define disease pathogenesis in acute respiratory distress syndrome (ARDS), and to develop rapid diagnostics to aid patient stratification and support targeted intervention. This is a programmatic approach to define disease pathogenesis in ARDS, and to develop rapid diagnostics to aid patient stratification and support targeted intervention.

WP1: ARDS: in whom to intervene? This will involve an unbiased informatics-based analysis of existing (HARP2, REST, MOSAIC, GALAXY, ARDS.NET) and new patient cohorts to define ARDS endotypes

WP2: ARDS: when to intervene? Undertake prospective analysis of trans-pulmonary cytokine, genomic/epigenomic and neutrophil and monocyte phenotyping/migration signatures, and novel imaging modalities (SPECT/CT, PET/CT) to define the optimal time for intervention in the above cohorts, and to develop rapid ('by lunchtime') diagnostic platforms. This WP will specifically test the concepts generated in well-established and highly refined animal, human lung slice and EVLP models of ALI

WP3: ARDS with what to intervene? The collaborative network established above will, together with GSK, be ideally positioned to deliver Phase IIa experimental POC studies, using existing assets in the specific subtypes identified; endpoints (e.g. vascular leak, cell migration, physiological indices, biomarkers) will be determined by the endotype under study